AptarGroup

Aptar Named a CDP Supplier Engagement Leader for the Fourth Consecutive Year

Retrieved on: 
Wednesday, March 20, 2024
General Health, Professional Services, Pharmaceutical, Sustainability, Recycling, Environment, Green Technology, Packaging, Climate Change, Environmental, Social and Governance (ESG), Manufacturing, Health, Carbon, CDP, Climate change, Innovation, ATR, Disclosure, Plastic, AptarGroup, Multimedia

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year.
  • View the full release here: https://www.businesswire.com/news/home/20240320103929/en/
    Graphic: Aptar is a 2023 CDP Supplier Engagement Leader (Graphic: Business Wire)
    CDP evaluates an organization’s engagement with their suppliers on climate change.
  • By evaluating supplier engagement and recognizing best practice, CDP aims to accelerate global action on supply chain emissions.
  • “Our fourth consecutive year as a CDP Supplier Engagement Leader reflects the strong collaboration between our Sustainability, Innovation and Purchasing teams where we strategically align with suppliers that are participating in our Supplier Screening process through platforms like EcoVadis,” said Beth Holland, Aptar’s Chief Sustainability Officer.

Aptar Pharma Continues Global Expansion with North America Capacity Extension at Congers, New York Site

Retrieved on: 
Thursday, March 14, 2024
Men, General Health, Pharmaceutical, Consumer, Packaging, Children, Biotechnology, Women, Transport, Seniors, Health, Logistics, Supply Chain Management, Manufacturing, Growth, CRSF, DMF, BOV, Drug Master File, GMP, Multimedia, AptarGroup, UDS

Aptar Pharma, part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site.

Key Points: 
  • Aptar Pharma, part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site.
  • This investment will help Aptar meet the growing prescription and consumer healthcare customer demand for proprietary drug delivery systems in North America.
  • Manufacturing capabilities at the Congers facility will be further expanded to offer even more innovative product solutions and increased production capacity to Aptar Pharma customers in North America.
  • “Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines,” commented Gael Touya, President, Aptar Pharma.

Lindus Health Unveils Versatile "All-in-One Respiratory CRO" Offering Tailored to Respiratory Clinical Trials

Retrieved on: 
Tuesday, April 2, 2024
Sleep apnea, Pneumonia, MIT, Electronic data capture, Patient, Chronic obstructive pulmonary disease, Research, Pi, Health information management, EDC, Electronic health record, MD, Respiratory disease, Asthma, CTMS, Housing, Clinical trial management system, COPD, Data management, AptarGroup, Clinical data management, Fine chemical

Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.

Key Points: 
  • Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.
  • "We're thrilled to be launching a bespoke CRO offering to respiratory disease sponsors to mitigate the challenges faced in bringing essential respiratory therapies to market."
  • Deep regulatory and therapeutic area-specific expertise: Bringing together various research backgrounds, the Lindus Health team resumes exceptional expertise within respiratory clinical trials and the ever-changing regulatory landscapes of the US, UK, and EU.
  • Lindus Health is committed to leading successful respiratory research, providing a robust and efficient framework for clinical trials from inception to completion, and enhancing the experience for both sponsors and participants.

Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies for the Sixth Consecutive Year

Retrieved on: 
Thursday, February 29, 2024
Environment, Packaging, Professional Services, Manufacturing, Sustainability, Health, Pharmaceutical, General Health, Environmental, Social and Governance (ESG), Multimedia, John Macarthur (wool pioneer), Targets, Biophysical environment, Growth, Social, Disclosure, AptarGroup, ESG, CDP, Climate change, Ellen, Organization, Science Based Targets initiative, Sustainable development, MacArthur Foundation, Science, ATR, Renewable energy

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the sixth consecutive year and is ranked number 29 out of 100 companies for 2024.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the sixth consecutive year and is ranked number 29 out of 100 companies for 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240229523803/en/
    “We are delighted to be named to Barron’s 100 Most Sustainable Companies for the sixth consecutive year for our leadership on sustainability efforts that help us, our employees, consumers, customers and community partners create a better future,” said Stephan B. Tanda, Aptar President and CEO.
  • Barron’s partnered with Calvert, a leader in ESG investing, to build the list of the most sustainable companies.
  • Barron’s full list of the 100 Most Sustainable Companies can be found here .

Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions

Retrieved on: 
Friday, February 9, 2024
General Health, Manufacturing, Health, Pharmaceutical, Packaging, ATR, Lupus, AptarGroup, Digital health, Neurology, Fatigue, Multimedia, BIIB, Immunology, Patient, Neuroscience, Multiple sclerosis

Aptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases.

Key Points: 
  • Aptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases.
  • As part of the agreement, Biogen will transfer ownership of select digital health solutions to Aptar Digital Health (Aptar).
  • In addition to these solutions, Biogen and Aptar will further collaborate to potentially develop and bring to market new digital health solutions for the management of spinal muscular amyotrophy, Friedreich’s ataxia and lupus in selected countries.
  • “We are excited to leverage our end-to-end capabilities to support Biogen and enable patients and their care teams to benefit from advanced digital solutions for better disease management,” said Pierre Leurent, President, Aptar Digital Health.

Aptar Reports Fourth Quarter and Annual 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Packaging, Pharmaceutical, Health, Manufacturing, Growth, ATR, Multimedia, AptarGroup, Acquisition, Cryptocurrency

Aptar reported net income of $62 million for the quarter, a 6% increase over the prior year.

Key Points: 
  • Aptar reported net income of $62 million for the quarter, a 6% increase over the prior year.
  • View the full release here: https://www.businesswire.com/news/home/20240208100452/en/
    “I am pleased to report that we delivered strong fourth quarter and full year results.
  • A big driver of this success can be attributed to our proprietary pharma dosing and dispensing systems, which reported over 20% core sales growth in the fourth quarter and double-digit growth for the year.
  • Our beauty dispensing solutions in fragrance also delivered double-digit core sales growth for 2023, rounding out a very successful year for us.

Aptar Named One of America’s Most Responsible Companies by Newsweek for the Fifth Consecutive Year

Retrieved on: 
Tuesday, January 23, 2024
Environment, Packaging, Chemicals, Plastics, Professional Services, Manufacturing, Sustainability, Green Technology, Environmental, Social and Governance (ESG), Recycling, AptarGroup, MacArthur Foundation, Statista, Ellen, Social, GRI, Responsibility, Partnership, John Macarthur (wool pioneer), Corporate social responsibility, CSR, Woman, ESG, ATR, Sustainable development, Pharmaceutical industry

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America’s Most Responsible Companies 2024 by Newsweek for the fifth consecutive year.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of America’s Most Responsible Companies 2024 by Newsweek for the fifth consecutive year.
  • Aptar is ranked number 29 out of 600 U.S. companies and is ranked first in its industry category.
  • View the full release here: https://www.businesswire.com/news/home/20240123575188/en/
    “We are extremely proud to be recognized by Newsweek for the fifth consecutive year.
  • Newsweek’s full list of America’s Most Responsible Companies 2024 can be found here .

Aptar Declares Quarterly Dividend and Announces 2024 Annual Meeting Details

Retrieved on: 
Thursday, January 18, 2024
General Health, Manufacturing, Health, Pharmaceutical, Packaging, AptarGroup, Interest, Shareholder, ATR, Central Time

The payment date is February 22, 2024, to stockholders of record as of February 1, 2024.

Key Points: 
  • The payment date is February 22, 2024, to stockholders of record as of February 1, 2024.
  • The Board also announced that the 2024 Annual Meeting of Stockholders will be held virtually on May 1, 2024, at 9:00 a.m. Central Time.
  • The record date for stockholders entitled to vote at the meeting is March 8, 2024.
  • More details regarding accessing the meeting will be shared as we get closer to the event.

Aptar to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Conference, ATR, AptarGroup, CFO

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced their participation at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced their participation at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.
  • Stephan Tanda, President and CEO, will present at 1:30 p.m. Eastern Standard Time.
  • Bob Kuhn, Executive Vice President and CFO, and Gael Touya, President Aptar Pharma, will also be available.

Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers

Retrieved on: 
Monday, December 4, 2023
FDA, Health, Science, Pharmaceutical, Research, CQA, NYSE, Food, Inhaler, ATR, Multimedia, AptarGroup, Pharmaceutical industry, Pharma

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).
  • View the full release here: https://www.businesswire.com/news/home/20231204794277/en/
    Moreover, Aptar’s study will help to define the potential target product profile of low-GWP propellant MDIs to achieve comparability in critical quality attributes (CQAs) to existing MDIs.
  • Additional capabilities Aptar can provide include pilot manufacturing / process, analytical methods offering alternative pathways to clinical trials, formulation development, metering valve technology and more.
  • Moreover, the study is expected to support the ongoing FDA efforts to provide guidance on the regulatory framework with respect to the evaluation and approval of low-GWP propellant MDIs.